AMBS >>NITRUZZZ BOUNCER// Appoints Russell Miller as Director of Investor Relations
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis, today announced it has appointed Russell Miller as Director of Investor Relations.
Mr. Miller previously served as Director of Investor Relations for US Data Works and for Force Protection, Inc. He has assisted in raising capital for companies both public and private, including real estate financing, development, and joint ventures for over 20 years. He has successfully participated in private placements, mezzanine financing, joint ventures, mergers and acquisitions, reverse mergers, national exchange up-listings and acquisitions for companies on the OTC, AMEX, and NASDAQ. As a consultant Mr. Miller has assisted a multitude of companies by developing their strategic plans for growth, liquidity, and return on equity by facilitating relationships with investment bankers, government relations officers, financiers, the media, and marketing and public relation firms. He has a broad range of worldwide contacts throughout the investment banking community, which include a large number of accredited investors and investment institutions.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in treating Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates for Parkinson’s and Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Contacts:
Media Contact
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
and
Investor Relations
Amarantus Bioscience Holdings, Inc.
Russell Miller, Director of Investor Relations
408-737-2734 x 109
ir@amarantus.com
Source: Amarantus BioScience Holdings, Inc.
AMBS NITRUZZZ BOUNCER// Appoints Russell Miller as Director
Top 10 Most Recent News Articles
White House Photographer Reveals Unseen Historic Moments
You don’t just wander into the White House and leave unimpressed, not if you're someone who lived it like David Hume Kennerly. Imagine stepping behind those gates and through history's lens, capturing moments few had the privilege to see. Kennerly's debut as the Chief White House Photographer was at a turning point in America, just after the Nixon saga collapsed in...
Continue Reading
DAR Logs Massive 587,000 Service Hours Nationwide
A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...
Continue Reading
ID Plans Secures Polaris Investment for Real Estate Boost
New Moves in Real Estate Tech Can you smell opportunity? Because it’s in the air down in Tampa where ID Plans just inked a deal with Polaris Growth Fund. We’re talking some serious private equity backing here aimed at ramping up what ID Plans can lay down in the commercial real estate sector. If you're not on this ride yet, it might be time to take a closer look....
Continue Reading
SeaWorld Rings in Holidays with All-New Festivities
Holiday Transformation at SeaWorld's Parks The holiday spirit isn't something you purchase—it’s an experience. And boy, SeaWorld seems to get this right. As the chill of late October settles in, SeaWorld parks across Orlando, San Diego, and San Antonio start dressing up for the holiday season, morphing into a spectacle of lights and festive joy. For anyone who’s...
Continue Reading
Energizer Set to Unveil Q4 and Full Year 2026 Results
Call in and Batten Down the Hatches November 17—Mark it. Energizer Holdings, Inc. (NYSE: ENR) is taking the stage to deliver its Fourth Quarter and full fiscal year 2026 financial showing. If you're tailing the power-boosting giant's dance in the market, then clear your morning schedule for a 10 a.m. ET webinar. CEO Mark LaVigne and CFO John Drabik are dialing up their...
Continue Reading
Famous Brands Slashes Fees to Boost Franchise Growth
Throwing a Sweet Deal for New Franchise Owners Talk about a move that’s got the industry buzzing—Famous Brands International, the folks behind Mrs. Fields and TCBY, just rolled out a tantalizing offer you don’t see every day. They’re slashing franchise fees and royalties by half for new franchisees who jump onboard before the ball drops on 2026. I’ll tell ya,...
Continue Reading
Armani/Casa Miami Earns Forbes Designation for Luxury
Where Luxury Meets Thoughtfulness Residences by Armani/Casa Miami just nabbed a VERIFIED™ Luxury Residences badge from the Forbes Travel Guide folks. Now, you might be wondering why this is significant or if it's just another shiny tag in a world already glistening with luxury concepts. Well, there's a shift happening here, and it's got some meat to it. The folks...
Continue Reading
kidSTREAM Museum Welcomes Carina Reeves as New CEO
Carina Reeves Takes the Helm at kidSTREAM You know how it goes—sometimes you need fresh leadership to steer the ship. That's exactly what's happening over at kidSTREAM Children's Museum. They've appointed Carina Reeves as their President and CEO after a nationwide hunt. This ain't just another CEO shuffle; it marks a pivotal moment as kidSTREAM inches closer to its...
Continue Reading
Max Stock Gears Up for Q3 Earnings Report Nov. 17
Max Stock's Q3 Earnings Anticipation Ah, it’s that time again—when we wait with bated breath for another round of quarterly earnings. Max Stock Ltd. (TASE: MAXO) is prepping to spill the beans on their third quarter 2026 performance, with a conference call scheduled for November 17. Big day? You bet. Who's Leading the Call? The brains behind the operation, CFO Paz Oz...
Continue Reading
Instacart's Strong Q3 Amid DoorDash Acquisition News
Bumper Profits and Bold Moves for Instacart Here's a twist in the grocery tech aisle—Instacart's got some hefty numbers rolling in for Q3 and a whopper of an acquisition announcement. What seemed like just another Tuesday in the market is shaken by Instacart's reveal of their third-quarter financial results, showcasing a significant year-over-year climb that would make...
Continue ReadingTop 5 Most Recently Viewed Articles
Transforming Retail with Vantage and Quid's Unique Partnership
Introduction to a New Era in Retail Intelligence In a rapidly evolving retail landscape, the partnership between Vantage Discovery and Quid marks a significant leap towards integrating advanced technology with consumer insights. Vantage Discovery, recognized for its cutting-edge AI-powered search and personalization solutions, is teaming up with Quid, a leader in trend...
Continue Reading
Ellington Financial Inc. Achieves Milestone in Non-QM Market
Ellington Financial Inc. Celebrates Non-QM Securitization Success Ellington Financial Inc. (NYSE: EFC) has reached a significant milestone with the successful closing of a $288 million securitization, which is backed by a pool of non-qualified residential mortgage (non-QM) loans. This achievement underscores the Company’s commitment to innovating in the mortgage market....
Continue Reading
Ryman Hospitality Properties, Inc. Enhances Investor Insights
Insights into Ryman Hospitality Properties, Inc. Ryman Hospitality Properties, Inc. (NYSE: RHP) is at the forefront of the hospitality and lodging industry, focusing on upscale group-oriented resorts and convention centers. This commitment to excellence enables the Company to provide memorable experiences, especially in country music entertainment. Updated Investor...
Continue Reading
Investing Insights: Understanding Your Rights as a Shareholder
Understanding Your Rights as a Shareholder Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is currently investigating significant transactions involving certain public companies and their shareholders' rights. The firm primarily focuses on potential violations of federal...
Continue Reading
Bambusa Therapeutics Secures Series A-2 Financing to Boost Development
Bambusa Therapeutics Completes Series A-2 Financing Successfully Bambusa Therapeutics, Inc., a prominent clinical-stage biotechnology firm specializing in next-generation bispecific antibodies for immunology and inflammation, has announced an important milestone: the completion of their oversubscribed Series A-2 financing. This achievement comes with a notable valuation...
Continue Reading